Becton, Dickinson and Company (BDXA) Stock Competitors & Peer Comparison
See (BDXA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.46% |
| BDX | $152.04 | +1.37% | 55.1B | 26.52 | $5.73 | +2.46% |
| ALC | $67.90 | +2.71% | 33.1B | 40.66 | $1.67 | +0.53% |
| MDLN | $36.01 | +6.54% | 30.5B | 31.59 | $1.14 | N/A |
| WST | $334.66 | +4.66% | 23.6B | 44.66 | $7.49 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.46% |
| COO | $68.62 | +2.74% | 13.4B | 34.14 | $2.01 | N/A |
| BAX | $20.03 | +4.11% | 10.3B | -10.48 | -$1.91 | +1.00% |
| ATR | $115.90 | +3.54% | 7.4B | 19.83 | $5.84 | +1.64% |
Stock Comparison
BDXA vs BDX Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BDX has a market cap of 55.1B. Regarding current trading prices, BDXA is priced at $59.24, while BDX trades at $152.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas BDX's P/E ratio is 26.52. In terms of profitability, BDXA's ROE is +0.05%, compared to BDX's ROE of +0.05%. Regarding short-term risk, BDXA is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check BDX's competition here
BDXA vs ALC Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ALC has a market cap of 33.1B. Regarding current trading prices, BDXA is priced at $59.24, while ALC trades at $67.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas ALC's P/E ratio is 40.66. In terms of profitability, BDXA's ROE is +0.05%, compared to ALC's ROE of +0.04%. Regarding short-term risk, BDXA is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check ALC's competition here
BDXA vs MDLN Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, MDLN has a market cap of 30.5B. Regarding current trading prices, BDXA is priced at $59.24, while MDLN trades at $36.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas MDLN's P/E ratio is 31.59. In terms of profitability, BDXA's ROE is +0.05%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, BDXA is less volatile compared to MDLN. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check MDLN's competition here
BDXA vs WST Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, WST has a market cap of 23.6B. Regarding current trading prices, BDXA is priced at $59.24, while WST trades at $334.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas WST's P/E ratio is 44.66. In terms of profitability, BDXA's ROE is +0.05%, compared to WST's ROE of +0.18%. Regarding short-term risk, BDXA is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check WST's competition here
BDXA vs HOLX Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, BDXA is priced at $59.24, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas HOLX's P/E ratio is 31.54. In terms of profitability, BDXA's ROE is +0.05%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BDXA is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check HOLX's competition here
BDXA vs BDXB Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BDXA is priced at $59.24, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BDXA's ROE is +0.05%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, BDXA is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check BDXB's competition here
BDXA vs COO Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, COO has a market cap of 13.4B. Regarding current trading prices, BDXA is priced at $59.24, while COO trades at $68.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas COO's P/E ratio is 34.14. In terms of profitability, BDXA's ROE is +0.05%, compared to COO's ROE of +0.03%. Regarding short-term risk, BDXA is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check COO's competition here
BDXA vs BAX Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BAX has a market cap of 10.3B. Regarding current trading prices, BDXA is priced at $59.24, while BAX trades at $20.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas BAX's P/E ratio is -10.48. In terms of profitability, BDXA's ROE is +0.05%, compared to BAX's ROE of -0.16%. Regarding short-term risk, BDXA is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check BAX's competition here
BDXA vs ATR Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ATR has a market cap of 7.4B. Regarding current trading prices, BDXA is priced at $59.24, while ATR trades at $115.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas ATR's P/E ratio is 19.83. In terms of profitability, BDXA's ROE is +0.05%, compared to ATR's ROE of +0.14%. Regarding short-term risk, BDXA is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check ATR's competition here
BDXA vs RGEN Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, RGEN has a market cap of 7.3B. Regarding current trading prices, BDXA is priced at $59.24, while RGEN trades at $130.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas RGEN's P/E ratio is 143.00. In terms of profitability, BDXA's ROE is +0.05%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, BDXA is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check RGEN's competition here
BDXA vs AVTR Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, AVTR has a market cap of 6.8B. Regarding current trading prices, BDXA is priced at $59.24, while AVTR trades at $9.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas AVTR's P/E ratio is -12.24. In terms of profitability, BDXA's ROE is +0.05%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, BDXA is more volatile compared to AVTR. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check AVTR's competition here
BDXA vs TFX Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, TFX has a market cap of 6B. Regarding current trading prices, BDXA is priced at $59.24, while TFX trades at $135.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas TFX's P/E ratio is 1940.43. In terms of profitability, BDXA's ROE is +0.05%, compared to TFX's ROE of -0.28%. Regarding short-term risk, BDXA is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check TFX's competition here
BDXA vs BLCO Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BLCO has a market cap of 5.6B. Regarding current trading prices, BDXA is priced at $59.24, while BLCO trades at $15.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas BLCO's P/E ratio is -25.25. In terms of profitability, BDXA's ROE is +0.05%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, BDXA is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check BLCO's competition here
BDXA vs STVN Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, STVN has a market cap of 4.9B. Regarding current trading prices, BDXA is priced at $59.24, while STVN trades at $18.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas STVN's P/E ratio is 30.66. In terms of profitability, BDXA's ROE is +0.05%, compared to STVN's ROE of +0.10%. Regarding short-term risk, BDXA is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check STVN's competition here
BDXA vs MMSI Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, MMSI has a market cap of 4B. Regarding current trading prices, BDXA is priced at $59.24, while MMSI trades at $67.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas MMSI's P/E ratio is 29.10. In terms of profitability, BDXA's ROE is +0.05%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BDXA is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check MMSI's competition here
BDXA vs HAE Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, BDXA is priced at $59.24, while HAE trades at $78.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas HAE's P/E ratio is 38.43. In terms of profitability, BDXA's ROE is +0.05%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BDXA is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check HAE's competition here
BDXA vs ICUI Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ICUI has a market cap of 3.5B. Regarding current trading prices, BDXA is priced at $59.24, while ICUI trades at $142.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas ICUI's P/E ratio is 76.34. In terms of profitability, BDXA's ROE is +0.05%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, BDXA is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check ICUI's competition here
BDXA vs WRBY Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, WRBY has a market cap of 3B. Regarding current trading prices, BDXA is priced at $59.24, while WRBY trades at $24.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas WRBY's P/E ratio is 2485.00. In terms of profitability, BDXA's ROE is +0.05%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, BDXA is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check WRBY's competition here
BDXA vs LMAT Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, BDXA is priced at $59.24, while LMAT trades at $96.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas LMAT's P/E ratio is 35.51. In terms of profitability, BDXA's ROE is +0.05%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, BDXA is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check LMAT's competition here
BDXA vs XRAY Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, XRAY has a market cap of 2.1B. Regarding current trading prices, BDXA is priced at $59.24, while XRAY trades at $10.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas XRAY's P/E ratio is -3.32. In terms of profitability, BDXA's ROE is +0.05%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, BDXA is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check XRAY's competition here
BDXA vs NVCR Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, BDXA is priced at $59.24, while NVCR trades at $17.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas NVCR's P/E ratio is -11.27. In terms of profitability, BDXA's ROE is +0.05%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, BDXA is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check NVCR's competition here
BDXA vs PLSE Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, PLSE has a market cap of 1.8B. Regarding current trading prices, BDXA is priced at $59.24, while PLSE trades at $25.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas PLSE's P/E ratio is -23.43. In terms of profitability, BDXA's ROE is +0.05%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, BDXA is more volatile compared to PLSE. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check PLSE's competition here
BDXA vs STAA Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, STAA has a market cap of 1.5B. Regarding current trading prices, BDXA is priced at $59.24, while STAA trades at $29.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas STAA's P/E ratio is -71.12. In terms of profitability, BDXA's ROE is +0.05%, compared to STAA's ROE of -0.06%. Regarding short-term risk, BDXA is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check STAA's competition here
BDXA vs ATRC Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ATRC has a market cap of 1.4B. Regarding current trading prices, BDXA is priced at $59.24, while ATRC trades at $27.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas ATRC's P/E ratio is -273.00. In terms of profitability, BDXA's ROE is +0.05%, compared to ATRC's ROE of -0.01%. Regarding short-term risk, BDXA is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check ATRC's competition here
BDXA vs BLFS Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BLFS has a market cap of 1.3B. Regarding current trading prices, BDXA is priced at $59.24, while BLFS trades at $27.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas BLFS's P/E ratio is -114.79. In terms of profitability, BDXA's ROE is +0.05%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, BDXA is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check BLFS's competition here
BDXA vs KMTS Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, BDXA is priced at $59.24, while KMTS trades at $19.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas KMTS's P/E ratio is -3.65. In terms of profitability, BDXA's ROE is +0.05%, compared to KMTS's ROE of -0.69%. Regarding short-term risk, BDXA is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check KMTS's competition here
BDXA vs AZTA Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, AZTA has a market cap of 1B. Regarding current trading prices, BDXA is priced at $59.24, while AZTA trades at $22.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas AZTA's P/E ratio is -9.43. In terms of profitability, BDXA's ROE is +0.05%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, BDXA is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check AZTA's competition here
BDXA vs QDEL Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, QDEL has a market cap of 950.6M. Regarding current trading prices, BDXA is priced at $59.24, while QDEL trades at $13.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas QDEL's P/E ratio is -0.78. In terms of profitability, BDXA's ROE is +0.05%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, BDXA is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check QDEL's competition here
BDXA vs ATRI Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BDXA is priced at $59.24, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BDXA's ROE is +0.05%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BDXA is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check ATRI's competition here
BDXA vs NNNN Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NNNN has a market cap of 709.3M. Regarding current trading prices, BDXA is priced at $59.24, while NNNN trades at $16.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas NNNN's P/E ratio is 107.73. In terms of profitability, BDXA's ROE is +0.05%, compared to NNNN's ROE of +0.23%. Regarding short-term risk, BDXA is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check NNNN's competition here
BDXA vs ANGO Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ANGO has a market cap of 509.9M. Regarding current trading prices, BDXA is priced at $59.24, while ANGO trades at $12.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas ANGO's P/E ratio is -16.24. In terms of profitability, BDXA's ROE is +0.05%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, BDXA is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check ANGO's competition here
BDXA vs OSUR Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, OSUR has a market cap of 291.9M. Regarding current trading prices, BDXA is priced at $59.24, while OSUR trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas OSUR's P/E ratio is -4.04. In terms of profitability, BDXA's ROE is +0.05%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, BDXA is more volatile compared to OSUR. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check OSUR's competition here
BDXA vs UTMD Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, UTMD has a market cap of 216.7M. Regarding current trading prices, BDXA is priced at $59.24, while UTMD trades at $68.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas UTMD's P/E ratio is 20.14. In terms of profitability, BDXA's ROE is +0.05%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, BDXA is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check UTMD's competition here
BDXA vs SMTI Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, SMTI has a market cap of 208.2M. Regarding current trading prices, BDXA is priced at $59.24, while SMTI trades at $22.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas SMTI's P/E ratio is 378.67. In terms of profitability, BDXA's ROE is +0.05%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, BDXA is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check SMTI's competition here
BDXA vs PDEX Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, PDEX has a market cap of 207.5M. Regarding current trading prices, BDXA is priced at $59.24, while PDEX trades at $65.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas PDEX's P/E ratio is 17.91. In terms of profitability, BDXA's ROE is +0.05%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, BDXA is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check PDEX's competition here
BDXA vs KRMD Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, KRMD has a market cap of 183.7M. Regarding current trading prices, BDXA is priced at $59.24, while KRMD trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas KRMD's P/E ratio is -80.00. In terms of profitability, BDXA's ROE is +0.05%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, BDXA is more volatile compared to KRMD. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check KRMD's competition here
BDXA vs INFU Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, INFU has a market cap of 181.5M. Regarding current trading prices, BDXA is priced at $59.24, while INFU trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas INFU's P/E ratio is 24.31. In terms of profitability, BDXA's ROE is +0.05%, compared to INFU's ROE of +0.14%. Regarding short-term risk, BDXA is more volatile compared to INFU. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check INFU's competition here
BDXA vs STXS Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, STXS has a market cap of 179.8M. Regarding current trading prices, BDXA is priced at $59.24, while STXS trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas STXS's P/E ratio is -7.67. In terms of profitability, BDXA's ROE is +0.05%, compared to STXS's ROE of -1.53%. Regarding short-term risk, BDXA is more volatile compared to STXS. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check STXS's competition here
BDXA vs MBOT Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, MBOT has a market cap of 82.9M. Regarding current trading prices, BDXA is priced at $59.24, while MBOT trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas MBOT's P/E ratio is -7.00. In terms of profitability, BDXA's ROE is +0.05%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, BDXA is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check MBOT's competition here
BDXA vs AKYA Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BDXA is priced at $59.24, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BDXA's ROE is +0.05%, compared to AKYA's ROE of -27.96%. Regarding short-term risk, BDXA is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check AKYA's competition here
BDXA vs DXR Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, DXR has a market cap of 51M. Regarding current trading prices, BDXA is priced at $59.24, while DXR trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas DXR's P/E ratio is 6.18. In terms of profitability, BDXA's ROE is +0.05%, compared to DXR's ROE of +0.22%. Regarding short-term risk, BDXA is more volatile compared to DXR. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check DXR's competition here
BDXA vs OMIC Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BDXA is priced at $59.24, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BDXA's ROE is +0.05%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BDXA is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check OMIC's competition here
BDXA vs IGAP Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BDXA is priced at $59.24, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BDXA's ROE is +0.05%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, BDXA is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check IGAP's competition here
BDXA vs ZTEK Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ZTEK has a market cap of 50.1M. Regarding current trading prices, BDXA is priced at $59.24, while ZTEK trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas ZTEK's P/E ratio is -7.76. In terms of profitability, BDXA's ROE is +0.05%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, BDXA is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check ZTEK's competition here
BDXA vs NYXH Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NYXH has a market cap of 50M. Regarding current trading prices, BDXA is priced at $59.24, while NYXH trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas NYXH's P/E ratio is -0.54. In terms of profitability, BDXA's ROE is +0.05%, compared to NYXH's ROE of -1.64%. Regarding short-term risk, BDXA is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check NYXH's competition here
BDXA vs STSS Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, STSS has a market cap of 49.1M. Regarding current trading prices, BDXA is priced at $59.24, while STSS trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas STSS's P/E ratio is -0.02. In terms of profitability, BDXA's ROE is +0.05%, compared to STSS's ROE of -1.66%. Regarding short-term risk, BDXA is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check STSS's competition here
BDXA vs POCI Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, POCI has a market cap of 43.9M. Regarding current trading prices, BDXA is priced at $59.24, while POCI trades at $5.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas POCI's P/E ratio is -8.87. In terms of profitability, BDXA's ROE is +0.05%, compared to POCI's ROE of -0.37%. Regarding short-term risk, BDXA is more volatile compared to POCI. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check POCI's competition here
BDXA vs NEPH Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NEPH has a market cap of 35.3M. Regarding current trading prices, BDXA is priced at $59.24, while NEPH trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas NEPH's P/E ratio is 46.43. In terms of profitability, BDXA's ROE is +0.05%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, BDXA is more volatile compared to NEPH. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check NEPH's competition here
BDXA vs MLSS Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, MLSS has a market cap of 33.8M. Regarding current trading prices, BDXA is priced at $59.24, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas MLSS's P/E ratio is -6.40. In terms of profitability, BDXA's ROE is +0.05%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, BDXA is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check MLSS's competition here
BDXA vs SDC Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BDXA is priced at $59.24, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas SDC's P/E ratio is -0.03. In terms of profitability, BDXA's ROE is +0.05%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BDXA is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check SDC's competition here
BDXA vs EKSO Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, EKSO has a market cap of 28.6M. Regarding current trading prices, BDXA is priced at $59.24, while EKSO trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas EKSO's P/E ratio is -2.31. In terms of profitability, BDXA's ROE is +0.05%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, BDXA is more volatile compared to EKSO. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check EKSO's competition here
BDXA vs HBIO Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, HBIO has a market cap of 27.2M. Regarding current trading prices, BDXA is priced at $59.24, while HBIO trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas HBIO's P/E ratio is -2.81. In terms of profitability, BDXA's ROE is +0.05%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, BDXA is more volatile compared to HBIO. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check HBIO's competition here
BDXA vs IVC Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BDXA is priced at $59.24, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas IVC's P/E ratio is -0.79. In terms of profitability, BDXA's ROE is +0.05%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BDXA is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check IVC's competition here
BDXA vs RVP Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, RVP has a market cap of 20.5M. Regarding current trading prices, BDXA is priced at $59.24, while RVP trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas RVP's P/E ratio is -3.11. In terms of profitability, BDXA's ROE is +0.05%, compared to RVP's ROE of -0.08%. Regarding short-term risk, BDXA is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check RVP's competition here
BDXA vs FEMY Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, FEMY has a market cap of 18.5M. Regarding current trading prices, BDXA is priced at $59.24, while FEMY trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas FEMY's P/E ratio is -1.09. In terms of profitability, BDXA's ROE is +0.05%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, BDXA is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check FEMY's competition here
BDXA vs ZJYL Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ZJYL has a market cap of 17.9M. Regarding current trading prices, BDXA is priced at $59.24, while ZJYL trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas ZJYL's P/E ratio is 11.45. In terms of profitability, BDXA's ROE is +0.05%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BDXA is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check ZJYL's competition here
BDXA vs ARTC Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ARTC has a market cap of 16.1M. Regarding current trading prices, BDXA is priced at $59.24, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas ARTC's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.05%, compared to ARTC's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check ARTC's competition here
BDXA vs RGNT Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, RGNT has a market cap of 9.5M. Regarding current trading prices, BDXA is priced at $59.24, while RGNT trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas RGNT's P/E ratio is -0.10. In terms of profitability, BDXA's ROE is +0.05%, compared to RGNT's ROE of N/A. Regarding short-term risk, BDXA is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check RGNT's competition here
BDXA vs NXGL Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NXGL has a market cap of 5.5M. Regarding current trading prices, BDXA is priced at $59.24, while NXGL trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas NXGL's P/E ratio is -1.49. In terms of profitability, BDXA's ROE is +0.05%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, BDXA is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check NXGL's competition here
BDXA vs NSTG Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BDXA is priced at $59.24, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BDXA's ROE is +0.05%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BDXA is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check NSTG's competition here
BDXA vs LUCY Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, LUCY has a market cap of 3.6M. Regarding current trading prices, BDXA is priced at $59.24, while LUCY trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas LUCY's P/E ratio is -0.58. In terms of profitability, BDXA's ROE is +0.05%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, BDXA is more volatile compared to LUCY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check LUCY's competition here
BDXA vs POAI Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, BDXA is priced at $59.24, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas POAI's P/E ratio is -0.03. In terms of profitability, BDXA's ROE is +0.05%, compared to POAI's ROE of -107.05%. Regarding short-term risk, BDXA is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check POAI's competition here
BDXA vs MHUA Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, BDXA is priced at $59.24, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas MHUA's P/E ratio is 0.25. In terms of profitability, BDXA's ROE is +0.05%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, BDXA is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check MHUA's competition here
BDXA vs NXGLW Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NXGLW has a market cap of 2M. Regarding current trading prices, BDXA is priced at $59.24, while NXGLW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, BDXA's ROE is +0.05%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, BDXA is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check NXGLW's competition here
BDXA vs GMVD Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BDXA is priced at $59.24, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BDXA's ROE is +0.05%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BDXA is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check GMVD's competition here
BDXA vs GMVDW Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BDXA is priced at $59.24, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.05%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BDXA is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check GMVDW's competition here
BDXA vs AVGR Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BDXA is priced at $59.24, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BDXA's ROE is +0.05%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BDXA is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check AVGR's competition here
BDXA vs STSSW Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, STSSW has a market cap of 887.9K. Regarding current trading prices, BDXA is priced at $59.24, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas STSSW's P/E ratio is -0.04. In terms of profitability, BDXA's ROE is +0.05%, compared to STSSW's ROE of +0.12%. Regarding short-term risk, BDXA is less volatile compared to STSSW. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check STSSW's competition here
BDXA vs LUCYW Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, BDXA is priced at $59.24, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas LUCYW's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.05%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, BDXA is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check LUCYW's competition here
BDXA vs GCTK Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, GCTK has a market cap of 293.7K. Regarding current trading prices, BDXA is priced at $59.24, while GCTK trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas GCTK's P/E ratio is 0.08. In terms of profitability, BDXA's ROE is +0.05%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, BDXA is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check GCTK's competition here
BDXA vs WOK Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, WOK has a market cap of 573. Regarding current trading prices, BDXA is priced at $59.24, while WOK trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas WOK's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.05%, compared to WOK's ROE of -0.07%. Regarding short-term risk, BDXA is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for BDXA.Check WOK's competition here
BDXA vs APR Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, APR has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas APR's P/E ratio is 22.59. In terms of profitability, BDXA's ROE is +0.05%, compared to APR's ROE of +9.81%. Regarding short-term risk, BDXA is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check APR's competition here
BDXA vs IVTY Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas IVTY's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.05%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, BDXA is more volatile compared to IVTY. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check IVTY's competition here
BDXA vs ATRS Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BDXA's ROE is +0.05%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BDXA is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check ATRS's competition here
BDXA vs HRC Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas HRC's P/E ratio is 41.92. In terms of profitability, BDXA's ROE is +0.05%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BDXA is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check HRC's competition here
BDXA vs IIN Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas IIN's P/E ratio is 226.45. In terms of profitability, BDXA's ROE is +0.05%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BDXA is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check IIN's competition here
BDXA vs ALOG Comparison June 2026
BDXA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 21.44, whereas ALOG's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.05%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, BDXA is more volatile compared to ALOG. This indicates potentially higher risk in terms of short-term price fluctuations for BDXA.Check ALOG's competition here